This successful TLC method cannot be deployed on its own in a clinical setting without a specially designed system to prevent patients and medical staff from being exposed to mobile phase fumes and silica dust from the TLC plate. This is addressed by our hermetically sealed cartridge design where the key feature is that the hermetic seal is maintained throughout loading, TLC plate development, and DOX and DOL band quantification. This prevents any toxic fumes from the mobile phase or toxic dust from the TLC plate from leaving the cartridge and potentially exposing patients and staff in the clinic. The need for a self-contained TLC process necessitated the use of a single mobile phase for streamlined plate development (Figure ). We show that running the TLC analysis inside the cartridge has a similar performance on patient samples as the traditional means of running the TLC plate validating this design.